Loteprednol Etabonate Ophthalmic Suspension, 0.2%, is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis
The product is expected to be launched in December 2023
The establishment of the facility demonstrates the company's commitment to delivering differentiated solutions to gynecology and pediatrics challenges
The LyondellBasell CirculenRenew polymers are made from renewable feedstocks derived from bio-based wastes
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
World HRD Congress is a well-known international body of Management Studies
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
The brands Aarne in Germany and Nalcrom in Canada and the Netherlands are being acquired
Subscribe To Our Newsletter & Stay Updated
